ImmuPharma PLC
  • Announcements
  • About Us
    • About Us
    • Our Team
    • Board of Directors
  • Our Science
    • Our Science
    • ImmuPharma Biotech
    • Key Clinical Investigators
  • Pipeline
    • Pipeline
    • Autoimmunity & Inflammation
    • Anti-Infectives
  • Partnerships & Collaborations
  • Investors
    • Investors
    • AIM Rule 26 Information
    • Regulatory News
    • Corporate Governance
    • Board of Directors
    • Annual Reports
    • Analyst Research
    • Interviews
    • Professional advisers
    • Email Alerts
  • Contact
Archives
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
October 11, 2024

Notification of Major Holding – Lanstead Capital

Read More
September 11, 2024

Extension of Warrants in Incanthera to 31 March 2025

Read More
September 09, 2024

INTERIM RESULTS for the six months ended 30 June 2024

Read More
August 06, 2024

TR1 – Major Holding – Lanstead

Read More
July 01, 2024

2024 Result of Annual General Meeting – all resolutions passed

Read More
June 05, 2024

Notice of AGM & Annual Report & Accounts

Read More
June 05, 2024

FINAL RESULTS for the twelve months ended 31 December 2023

Read More
June 03, 2024

Realisation of c£1.5 million on sale of shares in Incanthera plc

Read More
May 03, 2024

TR1 – Major Holding – Lanstead

Read More
April 24, 2024

IMMUPHARMA at BIO-EQUITY 2024 – 12-14 May 2024, San Sebastian

Read More
April 19, 2024

Grant of Share Options

Read More
April 03, 2024

New intellectual property strategy initiated to significantly enhance patent life and commercial value for P140 technology platform

Read More
  • 1
  • 2
  • 3
  • 4
  • …
  • 23
  • Keep up-to-date with email alerts

  • @immupharma

Aim Rule 26 Contact informationDisclaimerPrivacy PolicySite map

© ImmuPharma PLC 2005-2022 | All rights reserved